A Phase I, Open-label, Single and Multiple Dose Trial to Investigate Metabolism and Pharmacokinetics of [14C]BI 1467335 Administered as Oral Solution in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 18 May 2018
Price : $35 *
At a glance
- Drugs BI 1467335 (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis; Diabetic retinopathy; Non-alcoholic steatohepatitis; Renal fibrosis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 10 May 2018 Status changed from active, no longer recruiting to completed.
- 12 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 17 Jan 2018 Status changed from not yet recruiting to recruiting.